Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Equillium, Inc.
< Previous
1
2
Next >
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
November 13, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Stifel Healthcare Conference
November 13, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
October 07, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
September 10, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
August 28, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
August 06, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
July 18, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Participate in Upcoming Investor Conferences
July 02, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to be included in the Russell Microcap® Index
June 12, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
May 14, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 07, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
April 01, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
March 25, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
March 22, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
December 21, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
November 13, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 08, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
November 06, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Host Analyst & Investor Day
October 03, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the JonesTrading 2023 Healthcare Summit
October 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
September 20, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
August 30, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
August 09, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces $7.5 Million Share Repurchase Program
August 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
June 01, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 15, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.